Because the alterations of protein kinases and their pathways are involved in MTC development, several tyrosine kinase receptors inhibitors (TKIs) have been tested in vitro, preclinical, and clinical studies [66]. Here, NTRK1 is linked to medullary thyroid gland carcinoma.